Heartflow to Participate in the Morgan Stanley Technology, Media & Telecom Conference

Heartflow, Inc. (Nasdaq: HTFL), a frontrunner in AI technology for managing coronary artery disease (CAD), announced its participation in the upcoming Morgan Stanley Technology, Media & Telecom Conference. Scheduled for March 3, 2026, at 10:45 a.m. PT / 1:45 p.m. ET in San Francisco, the event will feature a fireside chat with Heartflow management. Interested investors can access a live and archived version of the discussion on the company’s Investor Relations website.

Heartflow has garnered recognition for its innovative approach to cardiovascular care, leveraging a vast dataset of over 160 million annotated coronary CTA images. This proprietary data underpins advanced AI models that provide clinicians with quick and accurate insights into CAD, enhancing patient outcomes through timely diagnoses. With adoption by more than 1,400 institutions globally, Heartflow continually expands its commercial footprint, supporting guidelines established by the American College of Cardiology (ACC) and the American Heart Association (AHA).

The company’s AI solutions have been validated in over 200 studies involving more than 365,000 patients, demonstrating a high acceptance rate of over 97% for coronary CTA images in clinical settings. Heartflow's integrated workflow allows healthcare providers to receive comprehensive analyses swiftly, facilitating prompt clinical decision-making while ensuring compliance with rigorous international standards like HITRUST and SOC 2 Type 2.

By transforming CAD into a condition that can be detected early and managed effectively, Heartflow is positioned at the forefront of cardiovascular innovation. Their Heartflow One platform produces personalized 3D heart models, revealing critical information about plaque characteristics and blood flow dynamics, thus minimizing the need for invasive procedures. As Heartflow shapes the future of cardiovascular care, stakeholders are invited to learn more about the company's initiatives and technological advancements at heartflow.com.

As Heartflow, Inc. prepares to participate in the upcoming Morgan Stanley Technology, Media & Telecom Conference, it presents a strategic moment for investors to reassess their position in the medical technology sector, particularly in AI applications for health diagnostics. Heartflow (Nasdaq: HTFL) has positioned itself as a frontrunner in the field of coronary artery disease (CAD) through its innovative use of artificial intelligence and extensive proprietary data.

The company’s robust technology and extensive validation through clinical research (over 600 peer-reviewed publications) highlight its credibility and effectiveness in improving patient outcomes. Its proprietary data pipeline built from over 160 million annotated CTA images diversifies its utility across various patient populations, suggesting that Heartflow is not just a niche player but a standard-setter in predictive cardiovascular care.

Current market conditions favor healthtech companies that can effectively integrate AI solutions into clinical workflows, particularly post-pandemic as healthcare providers are increasingly leaning towards technologies that enhance diagnostic accuracy and reduce time to treatment. Heartflow’s seamless clinical integration is a key advantage, enabling rapid quality-reviewed analyses that can significantly streamline decision-making for clinicians.

Investors should note the growing global adoption of Heartflow’s technology, with over 1,400 institutions relying on its solutions. This wide acceptance not only enhances the company’s revenue potential but also solidifies its market position as a trusted provider.

However, potential investors should stay alert for any regulatory changes or increased competition within the AI healthcare space. Monitoring the outcomes of Heartflow’s discussions at the conference could provide additional insights, especially regarding future partnerships, market expansion, and new product developments. In conclusion, Heartflow presents a compelling investment opportunity but warrants careful observation of market dynamics and competitive advances in AI technologies for healthcare.